Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Reider, S; Novacek, G; Haas, T; Gröchenig, HP; Platzer, R; Koch, R; Kump, PK; Reinisch, W; Moschen, A.
[Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH)].
Z Gastroenterol. 2023; 61(11):1518-1525
Doi: 10.1055/a-2150-2156
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Constantini-Kump Patrizia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The humanized monoclonal anti-α4β7-integrin-antibody vedolizumab is one of several biologic therapeutic options in moderate-to-severe ulcerative colitis and Crohn's disease. Within the VISIBLE trial program, a novel subcutaneous application route was evaluated in addition to the already established intravenous form. In this position statement, the working group "Inflammatory Bowel Diseases" of the Austrian Society for Gastroenterology and Hepatology (OEGGH) summarizes the evidence regarding the subcutaneous application of vedolizumab. This work supplements a position paper on the value of vedolizumab as a first-line biologic that has already been published and offers useful recommendations for clinical practice.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Gastroenterology - administration & dosage
- Austria - administration & dosage
- Inflammatory Bowel Diseases - drug therapy
- Colitis, Ulcerative - drug therapy
- Biological Products - therapeutic use
- Gastrointestinal Agents - therapeutic use
- Find related publications in this database (Keywords)
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Crohn's Disease